Loading company…
Sift Bio develops peptide-based immunotherapy treatments for cancer and autoimmune diseases.
Sift Bio uses AI, metagenomics, and T-cell screening to discover peptides for immunotherapy. Its platform is intended for biopharmaceutical companies and research institutions developing treatments for cancer and autoimmune diseases. Founded in 2024 in San Carlos, US, it raised USD 3.70 mn from Eisai Innovation and Freeflow Ventures.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in